Dendritic Cell-Targeted Theranostic Nanomedicine: Advanced Cancer Nanotechnology for Diagnosis and Therapy

References

• Bol KF , SchreibeltG, GerritsenWR, DeVries IJ, FigdorCG. Dendritic cell-based immunotherapy: state of the art and beyond. Clin. Cancer Res.22(8), 1897–1906 (2016).
   PubMed Web of Science ®Google Scholar
• Mohsenzadegan M , PengRW, RoudiR. Dendritic cell/cytokine‐induced killer cell‐based immunotherapy in lung cancer: what we know and future landscape. J. Cell. Physiol.235(1), 74–86 (2020).
   PubMed Web of Science ®Google Scholar
• Butterfield LH , RibasA, DissetteVBet al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res.9(3), 998–1008 (2003).
   PubMed Web of Science ®Google Scholar
• GuhaThakurta D , FanLQ, VuT, SheikhNA, TragerJB. Induction of antigen spread after sipuleucel-T treatment and its association with improved clinical outcome. J. Immunother. Cancer1(Suppl. 1), 101 (2013).
   Google Scholar
• Prince HM , WallDM, RitchieDet al. In vivo tracking of dendritic cells in patients with multiple myeloma. J. Immunother.31(2), 166–179 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang C , ShiG, ZhangJet al. Targeted antigen delivery to dendritic cell via functionalized alginate nanoparticles for cancer immunotherapy. J. Control. Rel.256, 170–181 (2017).
   PubMed Web of Science ®Google Scholar
• Shah NJ , NajibiAJ, ShihTYet al. A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia. Nat. Biomed. Eng.4(1), 40–51 (2020).
   PubMed Web of Science ®Google Scholar
• Muthu MS , MeiL, FengSS. Nanotheranostics: advanced nanomedicine for the integration of diagnosis and therapy. Nanomedicine (Lond.)9(9), 1277–1280 (2014).
   PubMed Web of Science ®Google Scholar
• De Vries IJ , LesterhuisWJ, BarentszJOet al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. Biotechnol.23(11), 1407–1413 (2005).
   PubMed Web of Science ®Google Scholar
• Viswanadh MK , MuthuMS. Targeted bioadhesive nanomedicine: an effective approach for synergistic drug delivery to cancers. Nanomedicine (Lond.)13, 1401–1403 (2018).
   PubMed Web of Science ®Google Scholar
• Cho NH , CheongTC, MinJHet al. A multifunctional core–shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat. Nanotechnol.6(10), 675–682 (2011).
   PubMed Web of Science ®Google Scholar
• Yang W , ZhuG, WangSet al. In situ dendritic cell vaccine for effective cancer immunotherapy. ACS Nano13(3), 3083–3094 (2019).
   PubMed Web of Science ®Google Scholar
• Xiang J , XuL, GongHet al. Antigen-loaded upconversion nanoparticles for dendritic cell stimulation, tracking, and vaccination in dendritic cell-based immunotherapy. ACS Nano9(6), 6401–6411 (2015).
   PubMed Web of Science ®Google Scholar
• Muthu MS , MehataAK, ViswanadhMK. Upconversion nanotheranostics: emerging designs for integration of diagnosis and therapy. Nanomedicine (Lond.)12(6), 577–580 (2017).
   PubMed Web of Science ®Google Scholar
• Muthu MS , AgrawalP, SinghS. Theranostic nanomedicine of gold nanoclusters: emerging platform for cancer diagnosis and therapy. Nanomedicine (Lond.)11(4), 327–330 (2016).
   PubMed Web of Science ®Google Scholar
• Podrazil M , HorvathR, BechtEet al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget6(20), 18192–18205 (2015).
   PubMed Web of Science ®Google Scholar
• Boudousquie C , BoandV, LingreEet al. Development and optimization of a GMP-compliant manufacturing process for a personalized tumor lysate dendritic cell vaccine. Vaccines8(1), 25 (2020).
   Web of Science ®Google Scholar
• Schadendorf D , UgurelS, Schuler-ThurnerBet al. Dacarbazine (DTIC) versus vaccination with autologous peptidepulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the DeCOG. Ann. Oncol.17(4), 563–570 (2006).
   PubMed Web of Science ®Google Scholar
• Beer TM , BernsteinGT, CormanJMet al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin. Cancer Res.17(13), 4558–4567 (2011).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov . Identifier: NCT01204684, Dendritic cell vaccine for patients with brain tumors. [National Library of Medicine (US), Bethesda (MD), cited 24 January 2020]; https://clinicaltrials.gov/ct2/show/NCT01204684
   Google Scholar